GeoVax Strengthens Patent Portfolio for Innovative Cancer Treatment Approach

Biotechnology company GeoVax Labs has expanded its intellectual property portfolio with a newly allowed patent that describes an innovative approach to treating solid tumors. The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application detailing a sophisticated therapeutic method targeting multiple cancer types, including glioblastoma, breast, prostate, head and neck, glioma, and lung cancers.

The patented strategy involves a precise three-step treatment process: first, direct intratumoral administration of an adenoviral vector encoding purine nucleoside phosphorylase (Ad/PNP), followed by local administration of the prodrug fludarabine phosphate, and culminating with radiation therapy. This synergistic approach is designed to generate targeted cytotoxic activity within the tumor microenvironment while minimizing systemic toxicity.

The newly allowed patent significantly strengthens GeoVax's Gedeptin intellectual property portfolio, which was previously licensed from PNP Therapeutics, Inc. and the University of Alabama at Birmingham. David Dodd, the company's Chairman and CEO, emphasized the strategic importance of this patent, noting that while it does not directly mirror current clinical programs, it establishes a critical foundation for future therapeutic developments.

The patent's significance extends beyond its immediate application. By providing intellectual property protection for this innovative treatment method, GeoVax is positioning itself at the forefront of targeted cancer therapy research. The approach offers several key advantages, including localized cytotoxicity, reduced systemic side effects, and potential synergy with existing immunotherapy treatments.

GeoVax's growing intellectual property estate now encompasses over 135 granted or pending patent applications across 23 distinct patent families. The company is currently preparing to launch a Phase 2 clinical trial combining Gedeptin with an Immune Checkpoint Inhibitor for patients with first recurrence of head and neck cancer, further demonstrating the potential of this innovative therapeutic approach.

The patent's allowance represents more than a legal milestone; it signals a potentially transformative approach to cancer treatment. By offering a method that can selectively target tumor cells while minimizing damage to surrounding healthy tissue, this technology could provide hope for patients with challenging-to-treat cancers.